Targeting the complement system: notes on therapeutic strategies for renal cancer.
作者信息
Lasorsa Francesco, Rutigliano Monica, Milella Martina, Ditonno Pasquale, Lucarelli Giuseppe
机构信息
Department of Precision and Regenerative Medicine and Ionian Area-Urology, Andrology and Kidney Transplantation Unit, University of Bari "Aldo Moro", Bari, Italy.
出版信息
Future Med Chem. 2025 May;17(9):979-981. doi: 10.1080/17568919.2025.2498876. Epub 2025 Apr 25.
Abstract
摘要
相似文献
1
Targeting the complement system: notes on therapeutic strategies for renal cancer.
Future Med Chem. 2025 May;17(9):979-981. doi: 10.1080/17568919.2025.2498876. Epub 2025 Apr 25.
3
Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field.
J Clin Med. 2025 Jun 13;14(12):4204. doi: 10.3390/jcm14124204.
4
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review.
Cancer Treat Rev. 2024 Jan;122:102652. doi: 10.1016/j.ctrv.2023.102652. Epub 2023 Nov 4.
6
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.
Clin J Am Soc Nephrol. 2024 Sep 1;19(9):1201-1208. doi: 10.2215/CJN.0000000000000505. Epub 2024 Jun 3.
7
Complement C3 inhibition reduces complement activation in clinical platelet concentrates but does not counteract platelet storage lesions.
Platelets. 2025 Dec;36(1):2513298. doi: 10.1080/09537104.2025.2513298. Epub 2025 Jun 25.
8
Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.
J Oncol Pract. 2016 May;12(5):412-20. doi: 10.1200/JOP.2016.011809.
9
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Eur Urol. 2017 Mar;71(3):426-436. doi: 10.1016/j.eururo.2016.11.020. Epub 2016 Dec 8.
10
The complement system in autoimmune diseases: pathogenesis, diagnostic markers, and therapeutic strategies.
Inflamm Res. 2025 Jun 30;74(1):93. doi: 10.1007/s00011-025-02061-0.
本文引用的文献
1
Transcriptomic and proteo-metabolic determinants of the grading system in clear cell renal cell carcinoma.
Urol Oncol. 2025 Mar 12. doi: 10.1016/j.urolonc.2025.02.016.
2
Beyond the Norm: The emerging interplay of complement system and extracellular matrix in the tumor microenvironment.
Semin Immunol. 2025 Mar;77:101929. doi: 10.1016/j.smim.2025.101929. Epub 2025 Jan 9.
3
The role of the complement system in the response to cytotoxic therapy.
Semin Immunol. 2025 Mar;77:101927. doi: 10.1016/j.smim.2024.101927. Epub 2025 Jan 6.
4
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.
Nat Commun. 2025 Jan 2;16(1):93. doi: 10.1038/s41467-024-55092-2.
5
The complement system in clinical oncology: Applications, limitations and challenges.
Semin Immunol. 2025 Mar;77:101921. doi: 10.1016/j.smim.2024.101921. Epub 2024 Dec 18.
6
Changes in complement C3a in the immunotherapy of advanced clear cell renal cell carcinoma.
Transl Androl Urol. 2024 Nov 30;13(11):2518-2526. doi: 10.21037/tau-24-549. Epub 2024 Nov 28.
7
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906.
8
Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options.
Biomedicines. 2024 Jun 28;12(7):1448. doi: 10.3390/biomedicines12071448.
9
The complement system as a target in cancer immunotherapy.
Eur J Immunol. 2024 Oct;54(10):e2350820. doi: 10.1002/eji.202350820. Epub 2024 Jul 12.
10
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody.
J Immunol. 2024 May 15;212(10):1589-1601. doi: 10.4049/jimmunol.2300728.
Zotero 插件